Skip to main content
SpringerLink
Log in

Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Primary membranoproliferativeglomerulonephritis (MPGN) has a poor long-termprognosis, with 40 per cent of patientsreaching end-stage renal failure after 10 yearsof observation. Approximately 35 per cent ofpatients die due to complications of thenephrotic syndrome. This study investigates theeffect of acetylsalicylic acid (ASA) combinedwith dipyridamole on proteinuria and renalfunction in nephrotic MPGN patients withnormal/moderately reduced glomerular filtration rate(GFR). Fourteen patients with biopsy-proventype I MPGN received ASA (1000 mg/day) anddipyridamole (300 mg/day) for 24 months.Proteinuria was reduced from 6.8 ± 2.4 g/dayto 1.1 ± 0.6 g/day (p < 0.001). Serumalbumin levels increased from 2.2 ± 0.5 g/dLto 3.7 ± 0.4 g/dL (p < 0.001) duringthe study period after 24 months compared tobaseline. Serum creatinine and GFR did notsignificantly change in patients treated withacetylsaliclylic acid and dipyridamole duringthe observation period (p < 0.05). Ourstudy suggests that ASA combined withdipyridamole significantly reduces proteinuria without impairing renal function in patientswith MPGN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Williams DG. Mesangiocapillary glomerulonephritis. In Davidson AM, Cameroon JS, Grünfeld JP, Kerr DNS, Ritz E, Winearls CG, eds, Oxford Textbook of Clinical Nephrology, 2nd edition, Vol 1, Oxford Publications, New York, 1998: 591–612

    Google Scholar 

  2. Glassock R. Membranoproliferative glomerulonephritis. In Ponticelli C, Glassock RJ, eds, Treatment of Primary Glomerulonephritis, Oxford Publications, New York, 1998: 218–233

    Google Scholar 

  3. Glassock R, Cohen A, Adler S. Primary glomerular disease. In Brenner B, ed, The Kidney, 5th edition, Vol 2, Philadelphia: WB Saunders Company, 1995: 1458–1466

    Google Scholar 

  4. Donadio JV, Offord K. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 1989 6: 445–451

    Google Scholar 

  5. Erbay B, Karatan O, Duman N. The effects of cyclosporine in idiopathic nephrotic syndrome resistant to immunosuppressive therapy. Transplant 1988; Proc 20(Suppl. 4): 292

  6. Tiller D, Clarkson A, Matthew T. A prospective rando-mized trial of the use of cyclophosphamide, dipyridamole and warfarin in membranous and membranoproliferative glomeru-lonephritis. In Proceedings of the 8th International Congress on Nephrology, 1981: 345–351

  7. Cattran DC, Cardella C, Roscoe J. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int1985 27: 436–441

    Google Scholar 

  8. Donadio JV, Anderson C, Mitchell J et al. Membranoprolife-rative glomerulonephritis, a clinical trial of platelet inhibitor therapy. N Engl J Med 1984; 310(22): 1421–1426

    Google Scholar 

  9. Knotkova V, Petru I, Nemecek K et al. Treatment of chronic proliferative glomerulonephritis using acetylsalicylic acid and dipyridamole. Cas Lek Cesk 1989; 128(26): 814–818

    Google Scholar 

  10. Zäuner I, Böhler J, Braun N. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoprolife-rative glomerulonephritis: a multi-centre prospective clinical trial. Nephrol Dial Transplant 1994; 9(6): 619–622

    Google Scholar 

  11. Levin A. Management of membranoproliferative glomeru-lonephritis: evidence-based recommendations. Kidney Int Suppl. 1999; 70: S41–46

    Google Scholar 

  12. Schmitt O, Bohle F, Reinecke T. Long-term prognosis of membranoproliferative glomerulonephritis type I. Nephron 1990; 55: 242–250

    Google Scholar 

  13. Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis 1987; 10: 157–171

    Google Scholar 

  14. Johnson RJ. Platelets in immune mediated glomerular disease. In Michinobu Otana, ed, Nephrology, Vol 1, Springer-Verlag, Tokyo, 1991: 191–200

    Google Scholar 

  15. George CRP, Clark WF, Cameron JS. The role of platelets in glomerulonephritis. Adv Nephrol 1975; 5(19): 512–518

    Google Scholar 

  16. Weeksler BB. Roles for human platelets in inflammation. Prog Clin Biol Res 1988; 283: 611–638

    Google Scholar 

  17. Patrono C, Pierucci A. Renal effect of nonsteroidal antiinflam-matory drugs in chronic glomerular disease. Am J Med 1986; 81(Suppl. 2b): 71–83

    Google Scholar 

  18. De la Cruz JP, Camara S, Frutos MA. Effect of dipyridamole with aspirin on urine protein excretion in patients with membranoproliferative glomerulonephritis. Eur J Clin Phar-macol 1992; 43: 307–309

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Şişli Etfal Training and Research Hospital, Istanbul, Turkey

    Özlem Harmankaya, Taner Baştürk, Yahya Öztürk, Nihat Karabiber & Aydoğan Öbek

Authors
  1. Özlem Harmankaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taner Baştürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yahya Öztürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nihat Karabiber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aydoğan Öbek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Özlem Harmankaya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harmankaya, Ö., Baştürk, T., Öztürk, Y. et al. Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol 33, 583–587 (2001). https://doi.org/10.1023/A:1019546617485

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1019546617485

Search

Navigation